surmount tirzepatide SURMOUNT‐4 study design. This is a phase 3, multicenter, randomized, Tirzepatide Further Cements Weight Loss

Recently, a real-world study showing association between incretin-based therapy and changes in taste perception with GLP-1 or dual GLP-1/GIP-RAs usage for around 40 weeks reported that independently to weight loss, there was an increase in sweet perception intensity up to 4.7 times and salt perception up to 3.2 times in around 20% of the participants, resulting as well in earlier satiety, and reduction of hunger and craving due to a major sensibilization to both flavors with any of these medication, although they did not mention further impact in weight loss or BMI change (170)

Both start at small doses and increase to help the body adjust

The incidence typically decreases over time as the body adapts to the medication, with many patients reporting improvement after several weeks at a stable dose

We discuss nutrition for training and how to match nutrition to training goals and metabolic flexibility